Bio-Rad Laboratories Inc, a multinational manufacturer and distributor of life science research and clinical diagnostic products, announces the European and Canadian launch of its BioPlex® 2200 Antiphospholipid Syndrome IgG, IgM, and IgA kits for use on its BioPlex® 2200 system. Antiphospholipid Syndrome is an autoimmune disease in which the body’s immune system mistakenly produces antibodies to certain blood proteins causing thrombosis (clotting) within arteries, veins, and small blood vessels.
Patients with Antiphospholipid Syndrome are at risk of strokes and heart attacks. In addition, thrombosis within arteries and veins has the potential to affect other organs such as the lungs, liver, and kidney.
The BioPlex 2200 Antiphospholipid Syndrome IgG, IgM, and IgA kits are used as an aid in the diagnosis of this disease by simultaneously detecting two autoantibodies (anti-Cardiolipin and anti-Beta-2 Glycoprotein I) and therefore leading to faster and better care for those suffering from this syndrome.
"The release of the Antiphospholipid Syndrome reflects our continued commitment to expand our menu around the BioPlex 2200 testing system," said John Goetz, Bio-Rad VP and group manager clinical diagnostics. "By obtaining multiplex results from a single patient sample, laboratories and physicians can get the answers they need to provide faster and more effective patient treatment."